Head & Neck Cancers

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

The John Theurer Cancer Center (JTCC) at Hackensack University Medical Center in New Jersey, one of the largest cancer centers in the United States

Useful Online Resources and Clinical Trials for Oral Cancer

A drug that delivers paclitaxel in a novel way has yielded favorable results in a phase II trial of patients with advanced esophageal cancer, prompting the company developing the drug to plan a phase III trial.

Data from the phase III ZETA trial show that vandetanib (Zactima), a selective tyrosine kinase inhibitor, significantly slows the progression of advanced medullary thyroid carcinoma

Identifying head and neck cancer patients who possess the FcyR genotype may help predict whether they will respond to monoclonal antibodies, which work by killing cancer cells bearing epidermal growth factor receptors (EGFR) on their surface.

Highlights from the 50th Annual Meeting of the American Society of Hematology.